Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 2Genitourinary 2Breast 2Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 33Radiosurgery 23Radiotherapy 21Sunitinib 20pembrolizumab 18Gemcitabine 16Cisplatin 16Androgen Antagonists 15Nivolumab 14enzalutamide 13Goserelin 13Prednisone 12Leuprolide 12Blood Specimen Collection 12Abiraterone Acetate 12bicalutamide 11aldesleukin 11Surveys and Questionnaires 11Cyclophosphamide 11Gonadotropin-Releasing Hormone 10Bevacizumab 10Multiparametric Magnetic Resonance Imaging 9Carboplatin 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Triptorelin Pamoate 8Radiotherapy, Intensity-Modulated 8Filgrastim 8Epirubicin 8Chemotherapy, Adjuvant 8Brachytherapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × tesetaxel × Genitourinary × Clear all
NCT01296243 2012-07-24

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Genta Incorporated

Phase 2 Unknown
57 enrolled
Genitourinary

Prostatic Neoplasms

NCT01215877 2012-07-11

Tesetaxel for Previously Treated Patients With Bladder Cancer

Genta Incorporated

Phase 2 Unknown
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡